Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. reports a corporate governance event dated July 13, 2016. The filing details the execution of a new employment agreement with Dr. Brian deGuzman, effective July 1, 2016.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $285,000 per year.
- Initial Bonus: $50,000.
- Annual Performance Bonus: Target of 40% of base salary (discretionary).
- Contract Term: Five years.
Material Changes
Dr. Brian deGuzman has been promoted from Chief Medical Officer to Executive Vice President while retaining his role as Chief Medical Officer. This change is accompanied by the formalization of his compensation and termination benefits under a new five-year agreement.
Guidance, Outlook, and Risks
The filing contains no financial guidance or market outlook. Key contractual provisions include:
- Termination Benefits: In the event of termination without "cause" or resignation with "good reason," Dr. deGuzman is entitled to his base salary through the end of the five-year term, plus expense reimbursements and accrued vacation. Death or disability triggers pro-rated bonus payments.
- Restrictive Covenants: The agreement includes non-compete restrictions for the duration of the term plus six months, covering employment with competitors, engaging in competing businesses, and soliciting customers or employees.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason."
- Confirm the impact of the new salary and bonus structure on the company's operating expenses.
- Review the company's cash position to ensure liquidity is sufficient to cover potential termination payouts (salary through the end of the term).